公司資料
Jazz Pharmaceuticals 股價、新聞與催化劑
- 股票代碼:
- JAZZ
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- Ireland
股票表現
248.36 USD (+1.39%)
收盤價
最後更新: 2026年8月17日
14.2B USD
市值
股價為何變動
As of Aug 17, 2026, JAZZ closed up 1.39% at $248.36. No new same-company headline was identified in the current news window.
公司概覽
業務概覽
Jazz Pharmaceuticals is a biopharmaceutical company focused on neuroscience, oncology, and sleep disorder therapies. Its portfolio mixes established commercial products with development programs aimed at extending the company’s specialty franchise.
所在地與產業分類
Headquartered in Ireland and listed on NASDAQ, Jazz has a global commercial footprint and a specialty-pharma identity. It sits in neuroscience and oncology rather than broad pharma.
商業模式特徵
The company generates value through specialty product sales, lifecycle management, and pipeline development in difficult-to-treat diseases. Investors watch revenue durability, patent and label risk, and the progress of new assets.
生技產業定位
Jazz occupies a steady specialty-biopharma position with catalyst sensitivity around pipeline and label updates. It is more commercial than a pure development-stage biotech name but still reacts to program milestones.
未來催化劑
- Jazz Pharmaceuticals’ catalysts are Xywav and oncology franchise execution, plus any pipeline update that extends the sleep-and-cancer mix. The key question is whether the update shows enough repeatable demand to look like a durable revenue driver rather than a one-quarter bump. If adoption broadens, sentiment can improve faster than the reported numbers alone would suggest.
近期新聞
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。